Cargando…
Biologically Aggressive Phenotype and Anti-cancer Immunity Counterbalance in Breast Cancer with High Mutation Rate
While cancer cells gain aggressiveness by mutations, abundant mutations release neoantigens, attracting anti-cancer immune cells. We hypothesized that in breast cancer (BC), where mutation is less common, tumors with high mutation rates demonstrate aggressive phenotypes and attract immune cells simu...
Autores principales: | Takahashi, Hideo, Asaoka, Mariko, Yan, Li, Rashid, Omar M., Oshi, Masanori, Ishikawa, Takashi, Nagahashi, Masayuki, Takabe, Kazuaki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7002588/ https://www.ncbi.nlm.nih.gov/pubmed/32024876 http://dx.doi.org/10.1038/s41598-020-58995-4 |
Ejemplares similares
-
The E2F Pathway Score as a Predictive Biomarker of Response to Neoadjuvant Therapy in ER+/HER2− Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020) -
Intratumoral Tumor Infiltrating Lymphocytes (TILs) are Associated With Cell Proliferation and Better Survival But Not Always With Chemotherapy Response in Breast Cancer
por: Wu, Rongrong, et al.
Publicado: (2023) -
CD8 T Cell Score as a Prognostic Biomarker for Triple Negative Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020) -
NR2F1, a Tumor Dormancy Marker, Is Expressed Predominantly in Cancer-Associated Fibroblasts and Is Associated with Suppressed Breast Cancer Cell Proliferation
por: Wu, Rongrong, et al.
Publicado: (2022) -
Enhanced immune response outperform aggressive cancer biology and is associated with better survival in triple-negative breast cancer
por: Oshi, Masanori, et al.
Publicado: (2022)